spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

IONTAS to Generate Antibodies using Mammalian Display Technology for a Global Biopharma

IONTAS to generate antibodies with favourable, binding and expression properties using their Mammalian Display Antibody Discovery Platform

Cambridge, UK, 22 January 2018: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, announced today that it has signed an agreement with Sanofi to discover antibodies using IONTAS’ proprietary Mammalian Display Technology.

IONTAS’ platform allows for the construction of large libraries of monoclonal cell lines each displaying a different IgG-formatted antibody on the cell surface. Novel binders can be isolated from the libraries by using fluorescence-activated cell sorting on the basis of antigen binding. Importantly, the system also has the potential to identify clones with development liabilities, such as self-aggregation, during the initial discovery phase.

Dr John McCafferty, CEO at IONTAS, commented: “Historically the consideration of developability issues have been addressed after selection of drug lead molecules. Our Mammalian Display Platform not only allows direct screening of millions of clones for binding affinity and specificity, but also has the potential for early identification of developability issues such as product precipitation. Such issues can derail product development resulting in significant losses in time and money.”

ENDS

IONTAS Ltd
Neil Butt, Chief Business Officer
Tel: +44 1223 750801
bd@iontas.co.uk

Zyme Communications
Lorna Cuddon
Tel: +44 (0)1223 968 920
lorna.cuddon@zymecommunications.com

About IONTAS
www.iontas.co.uk
IONTAS is a biotechnology company focused on antibody discovery and cutting-edge technology development. IONTAS offers services for antibody discovery using Phage Display Technology; and the supply of bespoke phage display libraries. In addition, IONTAS has developed proprietary antibody discovery platforms including Mammalian Display where full IgG antibodies are expressed in the context of a mammalian cell thereby allowing selection based on function, stability, expression and developability; and, KnotBody technology which facilitates the targeting of antibodies to ion channels, GPCRs and proteases.
 
Print this page
Send to a friend
   
spacer
News and Press Releases

BioIVT to Focus on the Application of In Vitro Hepatocyte Models in Toxicology Research at the North American ISSX Meeting

BioIVT, a leading provider of research models and services for drug development, today announced that it will be participating in several sessions at the 22nd North American International Society for the Study of Xenobiotics (ISSX) Meeting. This conference will be held from July 15-19 at the Palais des congrès de Montréal in Montréal, Canada.
More info >>


White Papers

Competitive Drive: The Challenges of a Globalised Packaging Industry

Aesica Pharmaceuticals

Packaging is becoming an increasingly competitive and lucrative industry globally. Jeremy Drummond PhD of Aesica Formulated Products looks at the challenges and opportunities this presents.
More info >>

Industry Events

6th Annual Single Cell Analysis Congress

8-9 November 2018, London, UK

Oxford Global is proud to present its 6th Annual Single Cell Analysis Congress taking place on 8-9 November 2018 in London.  Part of the Genomics & Synthetic Biology Series UK, the congress will bring together over 600 end users representing internationally renowned research & academic institutions, clinical research institutions, healthcare organisations as well as leading pharmaceutical and biotech companies.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement